14. Referenties

1.    Berden, F.A., et al., Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med, 2014. 72(8): p. 388-400.
2.    EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol, 2018; Available from: http://www.easl.eu/medias/cpg/2018/EASL%20Recommendations%20on%20Treatment%20of%20Hepatitis%20C%202018/English-report.pdf.
3.    AALS/ISDA Recommendations for Testing, Managing and Treating Hepatitis C. May 2018; Available from: https://www.hcvguidelines.org/.
4.    van der Meer, A.J., et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama, 2012. 308(24): p. 2584-93.
5.    Arends, J.E., et al., Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med, 2011. 69(1): p. 43-9.
6.    Lamers, M.H., et al., Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. Neth J Med, 2013. 71(7): p. 377-85.
7.    Boesecke, C., et al., Fueling the epidemic: low rates of spontaneous clearance of acute HCV coinfection, in Conference on Retroviruses and Opportunistic Infections. 2018: Boston.
8.    EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017. 66(1): p. 153-194.
9.    Basu, P.P., et al., Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. Slam C Study. Journal of Hepatology, 2016. 64(2): p. S806.
10.    Deterding, K., et al., Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis, 2017. 17(2): p. 215-222.
11.    Rockstroh, J.K., et al., Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. The Lancet Gastroenterology & Hepatology, 2017. 2(5): p. 347-353.
12.    EMA, Copegus: prescribing information. 2011.
13.    Bruchfeld, A., et al., Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat, 2006. 13(5): p. 316-21.
14.    FDA, Copegus, product information. 2011.
15.    EMA, Viekirax: Summary of product characteristics. 2015.
16.    Pockros, P.J., et al., LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study. Journal of Hepatology, 2015. 62: p. S257.
17.    EMA, Exviera: Summary of product characteristics. 2015.
18.    EMA, Zepatier: Summary of product characteristics. 2016.
19.    EMA, Maviret: Summary of product characteristics. 2017.
20.    Maan, R., et al., Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016. 14(12): p. 1821-1830.e6.
21.    EMA, Sovaldi: Summary of product characteristics. 2014.
22.    EMA, Daklinza: Summary of product characteristics. 2014.
23.    EMA, Harvoni: Summary of product characteristics. 2014.
24.    EMA, Epclusa: Summary of product characteristics. 2016.
25.    EMA, Vosevi: Summary of product characteristics. 2017.
26.    Back, D.J. and D.M. Burger, Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology, 2015. 149(6): p. 1315-7.
27.    Fontaine, H., et al., Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med, 2015. 373(19): p. 1886-8.


index.html